Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen Agent
1 other identifier
observational
829
1 country
18
Brief Summary
Prevalence rate of osteoporosis and it's actual management condition in Prostate cancer patients who takes LHRH antagonist and anti androgen
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2009
Shorter than P25 for all trials
18 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2009
CompletedFirst Submitted
Initial submission to the registry
December 1, 2009
CompletedFirst Posted
Study publicly available on registry
December 3, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2010
CompletedJune 30, 2010
June 1, 2010
4 months
December 1, 2009
June 28, 2010
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To define prevalence rate of osteoporosis in Prostate cancer patients who take LHRH antagonist or anti androgen (include MAB) at the stage of before treatment or it's initial stage.
Secondary Outcomes (1)
To assess whether proper osteoporosis prevention and treatment was given or not according to osteoporosis treatment guideline in prostate cancer patients who are enrolled in this study.
Eligibility Criteria
Korean prostate cancer patients who are taking LHRH antagonist or anti- androgen or both of them within 6 months since starting.
You may qualify if:
- pathologic confirmation of prostate cancer
- patients who are taking LHRH antagonist or anti- androgen or both of them within 6 months since starting.
You may not qualify if:
- patients who are hard to be analysed by limitation of chart record according to investigators'discretion
- patients who already have been registered in this study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (18)
Research Site
Cheonan-si, Chungcheongnam-do, South Korea
Research Site
Gangneung-si, Gangwon-do, South Korea
Research Site
Goyang-si, Gyeonggi-do, South Korea
Research Site
Guri-si, Gyeonggi-do, South Korea
Research Site
Gumi, Gyeongsangbuk-do, South Korea
Research Site
Gyeongju, Gyeongsangbuk-do, South Korea
Research Site
Masan-si, Gyeongsangnam-do, South Korea
Research Site
Iksan-si, Jeollabuk-do, South Korea
Research Site
Cheongju-si, North Chungcheong, South Korea
Research Site
Chungju, North Chungcheong, South Korea
Research Site
Daegu, South Korea
Research Site
Daejeon, South Korea
Research Site
Gwangju, South Korea
Research Site
Incheon, South Korea
Research Site
Jeju City, South Korea
Research Site
Pusan, South Korea
Research Site
Seoul, South Korea
Research Site
Ulsan, South Korea
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Joon Woo Bahn, MD
AstraZeneca Korea
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
December 1, 2009
First Posted
December 3, 2009
Study Start
November 1, 2009
Primary Completion
March 1, 2010
Study Completion
March 1, 2010
Last Updated
June 30, 2010
Record last verified: 2010-06